Catalent Pharma Names New CTO, SVP
Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical, where he lead new product development and licensing activities for both products and drug
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).